← MESOBLAST LTD (MESO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MESOBLAST LTD (MESO)
Biological Products, (No Diagnostic Substances) · market cap $2.0B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-07-15 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Mesoblast Ltd (MESO) is an Australian biotechnology company with 81 employees and a market capitalization of approximately $18.4 billion, developing allogeneic cell therapies across multiple indications. Its lead asset, rexlemestrocel-L, is in Phase 3 for Degenerative Disc Disease, with a broad pipeline spanning GvHD, Crohn's Disease, heart failure, and orthopedic indications. Financial details including cash, runway, and dilution are not disclosed in the available facts.
The catalyst path
- 2027-07-15 (est.)Phase 3 · Rexlemestrocel-L + HA mixtureimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rexlemestrocel-L | Phase 3 | Degenerative Disc Disease |
| Single Dose MPCs Injection | Phase 2 | Degenerative Disc Disease |
| adult human mesenchymal stem cells | Phase 3 | Crohn's Disease |
| Prochymal® | Phase 3 | Graft Versus Host Disease |
| MSB-CAR001 Combined With Hyaluronan | Phase 2 | Anterior Cruciate Ligament Injury |
| remestemcel-L | Phase 3 | Grade B aGVHD |
| Mesenchymal Precursor Cells (MPCs) | Phase 2 | Diabetic Nephropathy |
| NeoFuse | Phase 2 | Cervical Degenerative Disc Disease |
| Allogeneic Mesenchymal Precursor Cells | Phase 2 | Rheumatoid Arthritis |
| Mesenchymal Precursor Cells (MPC) 12.5 M | Phase 2 | Acute Myocardial Infarction |
| PROCHYMAL adult human mesenchymal stem cells | Phase 3 | Crohn's Disease |
| Prochymal™ adult human mesenchymal stem cells | Phase 2 | Crohn's Disease |
| Infusion of one MPC expanded cord unit and one unexpanded cord unit | Phase 3 | Acute Myelogenous Leukemia |
| Prochymal® - 2 Million cells/kg | Phase 2 | Graft Vs Host Disease |
| Allogeneic Mesenchymal Precursor Cells (MPCs) | Phase 3 | Chronic Heart Failure |
| Prochymal | Phase 2 | Graft Versus Host Disease |
| Lumbar Interbody Fusion with Autograft | Phase 2 | Degenerative Disc Disease |
| Prochymal™ | Phase 2 | Pulmonary Disease, Chronic Obstructive |
| Rexlemestrocel-L + HA mixture | Phase 3 | Degenerative Disc Disease |
| Mesenchymal Stem Cells | Phase 2 | Recovery Following Partial Medial Meniscectomy |
Price & technical context
3-month
+4.0%
6-month
-4.7%
12-month
-8.6%
52-wk range
$13.19–$20.96
vs 50-day MA
-7.7%
vs 200-day MA
-8.3%
Realized vol
55.6%
Max drawdown
-52.3%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MESO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.